The Risk of Depression in a Large Huntington Disease Population Compared With Controls: Analysis of the Enroll-HD Registry Data (P1-11.012)

Abstract

<h3>Objective:</h3> To describe the risk of depression among individuals with Huntington disease (HD; manifest) versus non-HD registry controls utilizing Enroll-HD data. <h3>Background:</h3> While high rates of depression have been reported in HD, real-world data on depression risk and risk factors in individuals with versus without HD by disease stage are incomplete. <h3>Design/Methods:</h3> Enroll-HD is a global observational registry for individuals with or at risk for HD, and their relatives. Data were collected annually (2013–31 October 2020; manifest, n=10,917; non-HD, n=4996). HD stage was estimated via Total Functional Capacity (TFC) score and Shoulson-Fahn staging: TFC 7–13/stage 1–2 (early), TFC 3–6/stage 3 (middle), TFC 0–2/stage 4–5 (late). Chorea severity was measured by Total Maximal Chorea (TMC) score (TMC 0–7/mild; TMC 8–28/moderate-to-severe), and depression by the Problem Behavioral Assessment binary scale. Odds ratios (ORs) were estimated via a logistic regression model controlling for multiple risk factors. <h3>Results:</h3> Early (OR, 1.84) and middle (1.45) TFC groups were associated with significantly higher risk of depression relative to the non-HD group (both <i>P</i>&lt;.001), but not the late group (1.10; <i>P</i>&gt;.25). Depression risk was lower in moderate-to-severe versus mild chorea (0.81, <i>P</i>&lt;.001), and for higher versus lower education (0.84, <i>P</i>&lt;.001). Depression risk was higher for the following (all <i>P</i>&lt;.01): ages 31–60 versus ≤30 years (1.18), females (1.53), overweight versus normal weight (1.13), obese versus normal weight (1.19), antipsychotic agents use (1.27), antidepressant agents use (1.58), smoking (1.18), alcohol problems (1.26), and drug abuse (1.32). <h3>Conclusions:</h3> Depression risk was higher in participants with versus without HD, with an increased risk during early HD stages, even after controlling for relevant risk factors for depression. These findings emphasize the need for attention to depression in early HD. <b>Disclosure:</b> Dr. Reshef has received personal compensation for serving as an employee of Teva. The institution of Mr. Smith has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Cytel Inc.. The institution of Dr. Harari has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Cytel Inc.. Dr. Gordon has received personal compensation for serving as an employee of Teva. Dr. Gordon has stock in Teva. Rinat Ribalov has received personal compensation for serving as an employee of TEVA. Dr. Lengil has received personal compensation for serving as an employee of Teva Pharmaceuticals. Dr. Leo has received personal compensation for serving as an employee of Teva Pharmaceutical Industries. Ms. Willock has received personal compensation for serving as an employee of HCD Economics. Dr. Robles-Zurita has received personal compensation for serving as an employee of HCD Economics. Dr. Robles-Zurita has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for HCD Economics. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Michael J. Fox Foundation. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva Pharmaceuticals. The institution of Dr. Furr-Stimming has received research support from Cures within Reach. The institution of Dr. Furr-Stimming has received research support from Huntington’s Disease Society of America. The institution of Dr. Furr-Stimming has received research support from Roche/Genetech. The institution of Dr. Furr-Stimming has received research support from Uniqure. The institution of Dr. Furr-Stimming has received research support from CHDI. The institution of Dr. Furr-Stimming has received research support from Huntington Study Group/Neurocrine. The institution of Dr. Furr-Stimming has received research support from NIH/University of Iowa. The institution of Dr. Furr-Stimming has received research support from Sage Therapeutics. Dr. Furr-Stimming has received publishing royalties from a publication relating to health care. Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Neuroscience. Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech.